BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.17.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261103
DTEND;VALUE=DATE:20261124
DTSTAMP:20260709T125124Z
CREATED:20260709T125124Z
LAST-MODIFIED:20260709T125124Z
UID:43917-1793664000-1795478399@www.pharmajournalist.com
SUMMARY:10th Dermatology Drug Development Summit
DESCRIPTION:10th Dermatology Drug Development Summit – Discovering\, Developing & Commercializing Next-Generation Inflammatory Skin Disease Therapeutics – November 3-5\, 2026 | Boston\, MA \nThe 10th Dermatology Drug Development Summit returns in 2026 as the leading premier forum dedicated to advancing the discovery\, development\, and commercialization of innovative therapies for inflammatory skin disease. \nMarking a decade of convening the field’s most influential voices\, this year’s summit arrives at a pivotal moment: As competition intensifies across atopic dermatitis and psoriasis\, developers are under growing pressure to demonstrate meaningful differentiation\, accelerate development timelines and identify the next generation of high-value opportunities beyond today’s established targets and therapies. \nDesigned as an intimate\, discussion-led forum\, the summit brings together more than 90 experts spanning discovery\, translational medicine\, preclinical development\, clinical strategy\, medical affairs\, and commercial functions. \nThe meeting provides a unique opportunity to benchmark emerging science\, evaluate novel targets\, and share practical lessons from across the dermatology pipeline. \nAttendees will hear from 40+ senior leaders representing major pharmaceutical companies\, innovative biotechs\, academic research centers\, and patient advocacy organizations\, with representation from AbbVie\, Galderma\, Merck\, SUN Pharma\, Eli Lilly\, UNION Therapeutics and others. \nThis year’s agenda features dual content tracks including Discovery & Preclinical and Clinical & Commercial. \nNew additions include a Pre-Conference Workshop Day\,  offering interactive deep dives into two of dermatology’s fastest-growing areas of innovation: hidradenitis suppurativa\, exploring strategies to drive earlier intervention and disease modification\, and rare & ultra-rare inflammatory skin diseases\, examining how developers can generate meaningful evidence\, overcome translational challenges and unlock scalable opportunities across underserved patient populations. \nWith 10+ hours of in-person networking\, the summit fosters meaningful collaboration among scientists\, clinicians\, executives\, and decisionmakers working to discover\, develop and commercialize the next wave of precision therapeutics. \nFor organizations committed to shaping the future of inflammatory skin disease drug development\, the Dermatology Drug Development Summit remains the essential annual meeting to align on emerging science\, evolving standards of care\, and the path to impactful patient outcomes. \nFind out more about the 10th Anniversary Edition of the Dermatology Drug Development Summit: https://ter.li/rcr0mcj
URL:http://www.pharmajournalist.com/event/10th-dermatology-drug-development-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261116
DTEND;VALUE=DATE:20261118
DTSTAMP:20260805T093959Z
CREATED:20260804T140412Z
LAST-MODIFIED:20260805T093959Z
UID:44087-1794787200-1794959999@www.pharmajournalist.com
SUMMARY:Biomarker Operations & Biospecimen Management Summit
DESCRIPTION:Hot off the press: The biomarker operations and biospecimen community finally has its own dedicated forum. \nIntroducing the inaugural Biomarker Operations & Biospecimen Management Summit\, the industry’s first\, purpose-built meeting for the heads\, VPs and leading stakeholders at pharma and biotech directly responsible for biospecimen and biomarker delivery. \nView the newly released agenda:  https://ter.li/p9sor70u \nWith trials growing in complexity\, rapidly expanding globally and becoming more data-intensive\, biomarker operations has emerged as the critical function for teams looking to advance biomarker- and multi-omics-driven therapies to market. \nAnswering the industry’s call to unite those collecting\, tracking and/or translating biospecimen data\, this meeting arrives at a pivotal moment. \nYou can expect to join 80+ experts to strategize on: \n\nElevating pre-analytical quality and site collection practices\, protecting biomarker signal integrity from the very first draw\nSecuring and storing biospecimens for the long term\, building acquisition\, biobanking\, and disposition strategies that balance cost\, compliance\, and future scientific value\nStreamlining biosample logistics\, kit management and vendor sourcing\, cutting waste and tracking errors so every sample reaches the right lab\, on time\nNavigating consent complexity and evolving regulation\, including IVDR and ICH E6(R3)\, to keep biospecimens compliant and usable for research\, long after collection\nEmbedding FAIR data principles and AI-driven automation into biomarker workflows\, replacing manual reconciliation with systems that accelerate decision-making\n\nAlongside this\, hear best-in-class strategies from AstraZeneca\, Regeneron\, Moderna\, BioNTech\, and Bristol Myers Squibb and real-time updates from Biospecimen Management Consortium (BMC). \nJoin us in collaboratively building the future playbook that will define the standards for precision medicine therapies. \nRegistration is complimentary* for qualifying biopharma and researchers. Visit the website to reserve your spot: https://ter.li/6v47cb7t
URL:http://www.pharmajournalist.com/event/biomarker-operations-biospecimen-management-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261117
DTEND;VALUE=DATE:20261120
DTSTAMP:20260813T160131Z
CREATED:20260813T160131Z
LAST-MODIFIED:20260813T160131Z
UID:44184-1794873600-1795132799@www.pharmajournalist.com
SUMMARY:2nd Model-Informed Drug Development Summit 2026
DESCRIPTION:As model-informed drug development (MIDD) becomes increasingly central to modern drug development strategy\, organizations are under growing pressure to leverage quantitative approaches that accelerate timelines\, reduce risk\, and improve regulatory and clinical success. The 2nd Model-Informed Drug Development Summit\, taking place November 17-19\, 2026\, in Boston\, MA\, brings together senior leaders in pharmacometrics\, clinical pharmacology\, quantitative sciences\, translational medicine\, and regulatory science to explore how modelling is transforming decision-making across the entire development lifecycle. \nDesigned as an intimate and highly interactive forum\, this summit moves beyond traditional large-scale industry meetings to provide meaningful peer-to-peer networking\, practical case studies\, and candid discussions on the real-world challenges of implementing MIDD strategies. Attendees will gain insights from leading organizations including FDA\, Health Canada\, Sanofi\, Eli Lilly\, GSK\, AbbVie\, Novartis\, Amgen\, Genentech\, Gilead Sciences\, BMS\, Astellas Pharma\, Vertex Pharmaceuticals\, Johnson & Johnson\, and Genmab. \nThe agenda explores the latest industry developments\, including implementation of the finalized ICH M15 guideline\, the growing role of quantitative systems pharmacology (QSP)\, advances in AI-enabled modelling\, and the use of real-world evidence to strengthen development decisions. Through case studies\, panel discussions\, workshops\, and roundtable sessions\, attendees will learn how to optimize dose selection\, improve trial design\, accelerate rare disease programs\, validate model outputs\, demonstrate return on investment from MIDD initiatives\, and strengthen regulatory submissions. \nIn addition to the main conference\, dedicated workshops will examine how to integrate pharmacometrics\, QSP\, machine learning\, and AI into connected modelling ecosystems\, while also addressing the challenge of building internal and external stakeholder confidence in modelling approaches. \nWith more than 60 senior industry leaders expected to attend\, the summit offers a unique opportunity to benchmark strategies\, share best practices\, build valuable partnerships\, and stay ahead of evolving regulatory and scientific expectations. Whether you are advancing innovative therapies\, refining quantitative development strategies\, or exploring the future role of AI in drug development\, this event provides the practical insights and connections needed to maximize the impact of model-informed approaches across your organization. \nTo learn more about the event and register online click here.
URL:http://www.pharmajournalist.com/event/2nd-model-informed-drug-development-summit-2026/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR